FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900976721> ?p ?o ?g. }

• W2900976721 endingPage "e93" @default.
• W2900976721 startingPage "301" @default.
• W2900976721 abstract "Abstract Lessons Learned Modification of FOLFIRINOX significantly improves safety and tolerability in Chinese patients with locally advanced pancreatic cancer. Patients with locally advanced pancreatic cancer benefit from neoadjuvant therapy and experience a much better survival than patients with upfront surgery. Background The objective of this study was to evaluate the efficacy of modified-FOLFIRINOX (mFOLFIRINOX) regimens in Chinese patients with locally advanced pancreatic cancer (LAPC) and to compare outcomes between patients with LAPC treated with mFOLFIRINOX-based neoadjuvant therapy (LAPC-N) and patients with LAPC who underwent upfront surgery (LAPC-S). Methods Forty-one patients with LAPC-N were enrolled prospectively. Imaging features, chemotherapy response, adverse events, perioperative complications, histology, and survival were analyzed. Seventy-four patients with resectable pancreatic cancer (RPC) (from April 2012 to November 2017) and 19 patients with LAPC-S (from April 2012 to March 2014) were set as observational cohorts, and data were collected retrospectively. LAPC-N patients with adequate response underwent surgical treatment, whereas continuous chemotherapy was given to LAPC-N patients who were not deemed resectable after treatment, and the response was re-evaluated every 2 months. Results Forty-one patients with LAPC received mFOLFIRINOX with a response rate of 37.1%. The most common severe adverse events were neutropenia and anemia. mFOLFIRINOX-based neoadjuvant therapy contributed to a remarkable decrease in CA19-9 level and tumor diameter. Fourteen LAPC-N patients underwent surgery (LAPC-N-S) after downstaging. Compared with LAPC-N-S cases, LAPC-S patients had longer operative time, more blood loss, and a higher risk of grade 5 complications. The median overall survival (OS) and progression-free survival (PFS) of LAPC-N-S patients were 27.7 months and 19.3 months, respectively, which were similar to those of patients with RPC (30.0 months and 23.0 months) and much longer than those of patients with LAPC-S (8.9 months and 7.6 months), respectively. Conclusion Neoadjuvant chemotherapy such as the mFOLFIRINOX regimen can be recommended for Chinese patients with LAPC after dose modification. Patients with LAPC-N who underwent surgery obtained significantly improved survival compared with patients in the observational LAPC-S cohort, who did not undergo neoadjuvant therapy." @default.
• W2900976721 created "2018-11-29" @default.
• W2900976721 creator A5000292144 @default.
• W2900976721 creator A5003319267 @default.
• W2900976721 creator A5013855342 @default.
• W2900976721 creator A5015743363 @default.
• W2900976721 creator A5017140872 @default.
• W2900976721 creator A5026984704 @default.
• W2900976721 creator A5027311139 @default.
• W2900976721 creator A5039295714 @default.
• W2900976721 creator A5040527192 @default.
• W2900976721 creator A5044014447 @default.
• W2900976721 creator A5046844707 @default.
• W2900976721 creator A5052421307 @default.
• W2900976721 creator A5072707334 @default.
• W2900976721 creator A5075441683 @default.
• W2900976721 creator A5079944301 @default.
• W2900976721 creator A5080959496 @default.
• W2900976721 creator A5085378930 @default.
• W2900976721 date "2018-11-20" @default.
• W2900976721 modified "2023-10-15" @default.
• W2900976721 title "Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population" @default.
• W2900976721 cites W1826768932 @default.
• W2900976721 cites W1834579309 @default.
• W2900976721 cites W1906085213 @default.
• W2900976721 cites W1955000909 @default.
• W2900976721 cites W1999139441 @default.
• W2900976721 cites W2014397931 @default.
• W2900976721 cites W2039928533 @default.
• W2900976721 cites W2054625398 @default.
• W2900976721 cites W2079418758 @default.
• W2900976721 cites W2090481758 @default.
• W2900976721 cites W2121608920 @default.
• W2900976721 cites W2142795752 @default.
• W2900976721 cites W2149693540 @default.
• W2900976721 cites W2152387274 @default.
• W2900976721 cites W2168645047 @default.
• W2900976721 cites W2170552969 @default.
• W2900976721 cites W2192219942 @default.
• W2900976721 cites W2317504614 @default.
• W2900976721 cites W2345822778 @default.
• W2900976721 cites W2735949777 @default.
• W2900976721 doi "https://doi.org/10.1634/theoncologist.2018-0696" @default.
• W2900976721 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6519772" @default.
• W2900976721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30459238" @default.
• W2900976721 hasPublicationYear "2018" @default.
• W2900976721 type Work @default.
• W2900976721 sameAs 2900976721 @default.
• W2900976721 citedByCount "20" @default.
• W2900976721 countsByYear W29009767212019 @default.
• W2900976721 countsByYear W29009767212020 @default.
• W2900976721 countsByYear W29009767212021 @default.
• W2900976721 countsByYear W29009767212022 @default.
• W2900976721 countsByYear W29009767212023 @default.
• W2900976721 crossrefType "journal-article" @default.
• W2900976721 hasAuthorship W2900976721A5000292144 @default.
• W2900976721 hasAuthorship W2900976721A5003319267 @default.
• W2900976721 hasAuthorship W2900976721A5013855342 @default.
• W2900976721 hasAuthorship W2900976721A5015743363 @default.
• W2900976721 hasAuthorship W2900976721A5017140872 @default.
• W2900976721 hasAuthorship W2900976721A5026984704 @default.
• W2900976721 hasAuthorship W2900976721A5027311139 @default.
• W2900976721 hasAuthorship W2900976721A5039295714 @default.
• W2900976721 hasAuthorship W2900976721A5040527192 @default.
• W2900976721 hasAuthorship W2900976721A5044014447 @default.
• W2900976721 hasAuthorship W2900976721A5046844707 @default.
• W2900976721 hasAuthorship W2900976721A5052421307 @default.
• W2900976721 hasAuthorship W2900976721A5072707334 @default.
• W2900976721 hasAuthorship W2900976721A5075441683 @default.
• W2900976721 hasAuthorship W2900976721A5079944301 @default.
• W2900976721 hasAuthorship W2900976721A5080959496 @default.
• W2900976721 hasAuthorship W2900976721A5085378930 @default.
• W2900976721 hasBestOaLocation W29009767211 @default.
• W2900976721 hasConcept C121608353 @default.
• W2900976721 hasConcept C126322002 @default.
• W2900976721 hasConcept C141071460 @default.
• W2900976721 hasConcept C143998085 @default.
• W2900976721 hasConcept C197934379 @default.
• W2900976721 hasConcept C2776694085 @default.
• W2900976721 hasConcept C2777063308 @default.
• W2900976721 hasConcept C2777148230 @default.
• W2900976721 hasConcept C2778292576 @default.
• W2900976721 hasConcept C2780210213 @default.
• W2900976721 hasConcept C2780258809 @default.
• W2900976721 hasConcept C2780962732 @default.
• W2900976721 hasConcept C526805850 @default.
• W2900976721 hasConcept C530470458 @default.
• W2900976721 hasConcept C71924100 @default.
• W2900976721 hasConceptScore W2900976721C121608353 @default.
• W2900976721 hasConceptScore W2900976721C126322002 @default.
• W2900976721 hasConceptScore W2900976721C141071460 @default.
• W2900976721 hasConceptScore W2900976721C143998085 @default.
• W2900976721 hasConceptScore W2900976721C197934379 @default.
• W2900976721 hasConceptScore W2900976721C2776694085 @default.
• W2900976721 hasConceptScore W2900976721C2777063308 @default.
• W2900976721 hasConceptScore W2900976721C2777148230 @default.
• W2900976721 hasConceptScore W2900976721C2778292576 @default.
• W2900976721 hasConceptScore W2900976721C2780210213 @default.

• next